BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37958201)

  • 1. Diagnostic Value of Preoperative uPAR-PET/CT in Regional Lymph Node Staging of Oral and Oropharyngeal Squamous Cell Carcinoma: A Prospective Phase II Trial.
    Lawaetz M; Christensen A; Juhl K; Lelkaitis G; Karnov K; Carlsen EA; Charabi BW; Loft A; Czyzewska D; Buchwald CV; Kjaer A
    Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of Urokinase-Type Plasminogen Activator Receptor PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with
    Risør LM; Clausen MM; Ujmajuridze Z; Farhadi M; Andersen KF; Loft A; Friborg J; Kjaer A
    J Nucl Med; 2022 Aug; 63(8):1169-1176. PubMed ID: 34857658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-Type Plasminogen Activator Receptor (uPAR) Expression and [
    Lawaetz M; Binderup T; Christensen A; Juhl K; Lelkaitis G; Lykke E; Knudsen L; von Buchwald C; Kjaer A
    Mol Imaging Biol; 2023 Dec; 25(6):1034-1044. PubMed ID: 37749438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma.
    Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A
    J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Dosimetry, and Tumor Detection Ability of
    Skovgaard D; Persson M; Brandt-Larsen M; Christensen C; Madsen J; Klausen TL; Holm S; Andersen FL; Loft A; Berthelsen AK; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
    J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Phase II Trial of Prognostication by
    Carlsen EA; Loft M; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
    J Nucl Med; 2022 Sep; 63(9):1371-1377. PubMed ID: 35058319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate preoperative staging with [
    Chen S; Chen Z; Zou G; Zheng S; Zheng K; Zhang J; Huang C; Yao S; Miao W
    Eur Radiol; 2022 Sep; 32(9):6070-6079. PubMed ID: 35352157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial.
    Fosbøl MØ; Kurbegovic S; Johannesen HH; Røder MA; Hansen AE; Mortensen J; Loft A; Petersen PM; Madsen J; Brasso K; Kjaer A
    J Nucl Med; 2021 Mar; 62(3):354-359. PubMed ID: 32764119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts.
    Persson M; Liu H; Madsen J; Cheng Z; Kjaer A
    Nucl Med Biol; 2013 Jul; 40(5):618-24. PubMed ID: 23602763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.
    Adams S; Baum RP; Stuckensen T; Bitter K; Hör G
    Eur J Nucl Med; 1998 Sep; 25(9):1255-60. PubMed ID: 9724374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved positron emission tomography imaging of glioblastoma cancer using novel
    Loft MD; Sun Y; Liu C; Christensen C; Huang D; Kjaer A; Cheng Z
    Amino Acids; 2017 Jun; 49(6):1089-1100. PubMed ID: 28316028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of 18-F Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Imaging in Primary Staging of Squamous Cell Carcinoma of the Oral Cavity.
    Linz C; Brands RC; Herterich T; Hartmann S; Müller-Richter U; Kübler AC; Haug L; Kertels O; Bley TA; Dierks A; Buck AK; Lapa C; Brumberg J
    JAMA Netw Open; 2021 Apr; 4(4):e217083. PubMed ID: 33881529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study.
    Fosbøl MØ; Mortensen J; Petersen PM; Loft A; Madsen J; Kjaer A
    Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34198666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
    Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
    Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of positron emission tomography/ computed tomography in the initial staging of head and neck squamous cell carcinoma: Accuracy in evaluation of the primary site of the tumor, metastases to cervical lymph nodes, and distant metastases.
    Krátká Z; Paska J; Kavka A; Jaruskova M; Lohynska R; Lickova K; Cocek A
    Otolaryngol Pol; 2022 Sep; 76(6):14-21. PubMed ID: 36805981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental Impact of [
    Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [
    Khare HA; Døssing KBV; Ringgaard L; Christensen E; Urbak L; Sillesen H; Ripa RS; Binderup T; Pedersen SF; Kjaer A
    Atherosclerosis; 2022 Jul; 352():103-111. PubMed ID: 35396143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluorodeoxyglucose uptake level-based lymph node staging in oropharyngeal squamous cell cancer--role of molecular marker expression on diagnostic outcome.
    Sadick M; Weiss C; Piniol R; Frey S; Hoermann K; Schoenberg SO; Sadick H
    Oncol Res Treat; 2015; 38(1-2):16-22. PubMed ID: 25633529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of SUVmax in (18)F-FDG PET/CT scan for detecting nodal metastases in patients with oral squamous cell carcinoma.
    Kitajima K; Suenaga Y; Minamikawa T; Komori T; Otsuki N; Nibu K; Sasaki R; Itoh T; Sugimura K
    Springerplus; 2015; 4():718. PubMed ID: 26636006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.